Federal contract award
75A50123C00064
R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN15 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPENSES FOR R&D FACILITIES AND MAJOR EQUIPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $748.0K |
| Current contract value | $748.0K |
| Potential contract value / ceiling | $748.0K |
| Start date | Sep 25, 2023 |
| Current end date | Jan 30, 2026 |
| Potential end date | Jan 30, 2026 |
| Latest award activity | Mar 20, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Mar 20, 2025 | P00002 | $0 | R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT |
| Jun 20, 2024 | P00001 | $0 | R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT |
| Sep 25, 2023 | 0 | $748.0K | R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.